Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Australia's CSL in exclusive talks for $7 billion buyout of Swiss Vifor Pharma - report

Published 02/12/2021, 10:49
Updated 02/12/2021, 23:50
© Reuters. FILE PHOTO: A company logo is pictured on the CSL Behring building in Bern, Switzerland, June 15, 2017. REUTERS/Denis Balibouse

© Reuters. FILE PHOTO: A company logo is pictured on the CSL Behring building in Bern, Switzerland, June 15, 2017. REUTERS/Denis Balibouse

(Reuters) - Australian biopharmaceutical giant CSL Ltd is in exclusive talks to buy Swiss drugmaker Vifor Pharma in a A$10 billion ($7 billion) deal, Australian media reported, sending the Swiss drugmaker's shares up by a fifth.

After discussing a potential deal since March, the companies were now in advanced talks and CSL, the world's largest maker of blood plasma treatments, was carrying out due diligence on the Swiss firm, according to reports in The Australian Financial Review and The Australian.

The reports said the deal valued the Swiss company, which makes prescription medications and is focused on treatment of kidney disease, at about A$10 billion without giving further details about the potential deal.

Both Vifor Pharma and CSL said in separate statements that they will not comment on the speculation.

Morgan Stanley (NYSE:MS) analysts said in a research note that CSL may be seeking diversification because blood plasma collections - where it pays people to give blood, which it then converts to treatments - remained depressed due to COVID-19 restrictions.

"Diversification could be wise, although it could lead to near-term de-rating until any potential synergies are evident to the market," the Morgan Stanley note said.

Jefferies analysts said in a note that the potential buyout would be "a departure in terms of therapeutic area for CSL but does tie into their nascent kidney transplant franchise".

© Reuters. FILE PHOTO: The logo of Swiss drugmaker Vifor Pharma is seen at the company's headquarters in Glattbrugg, Switzerland November 16, 2020. REUTERS/Arnd Wiegmann

Vifor's shares closed 21% higher at the top of Swiss mid-cap index on Thursday. CSL shares were down 1% in early trading on Friday, against a slightly higher overall market.

($1 = 1.4083 Australian dollars)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.